Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 2022 | 330 pages | ID: DBDC6183F678EN
Global Markets Direct

Abstracts

Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Drugs In Development, 2022, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the 'bad' low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the 'good' high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 34, 21, 27, 3, 38, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Dyslipidemia - Overview
Dyslipidemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dyslipidemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dyslipidemia - Companies Involved in Therapeutics Development
Dyslipidemia - Drug Profiles
Dyslipidemia - Dormant Projects
Dyslipidemia - Discontinued Products
Dyslipidemia - Product Development Milestones
Featured News & Press Releases
Feb 25, 2022: Arrowhead concludes enrolment in Phase IIb mixed dyslipidemia trial
Dec 22, 2021: Akeso: Early completion of patient enrollment of Ebronucimab (PCSK9 monoclonal antibody, AK102) in a phase III clinical trial for primary hypercholesterolemia and mixed hyperlipidemia in China
Nov 15, 2021: Arrowhead presents new clinical data on ARO-APOC3 at AHA 2021
Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial
Nov 03, 2021: Ionis begins clinical trial of severe hypertriglyceridemia medicine
Nov 02, 2021: Rivus reports positive data from trial of cardiometabolic disease therapy
Sep 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of ARO-APOC3 for treatment of mixed dyslipidemia
Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins
Jul 06, 2021: Novartis announces complete response resubmission for inclisiran new drug application
Jun 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-ANG3 for treatment of mixed dyslipidemia
Jun 03, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-APOC3 for treatment of severe hypertriglyceridemia
May 16, 2021: tctMD: Evinacumab lowers triglycerides in severe hypertriglyceridemia
Mar 22, 2021: JW Pharmaceutical: Proving the effect of improving lipids as a result of phase 3 clinical trial of RivaroJet 'NDA application'
Mar 01, 2021: Arrowhead Pharmaceuticals files IND to begin phase 2b study of ARO-APOC3 in patients with severe hypertriglyceridemia
Feb 01, 2021: Matinas BioPharma announces topline results from ENHANCE-IT study of LYPDISO against Vascepa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Dyslipidemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dyslipidemia - Pipeline by 89bio Inc, 2022
Dyslipidemia - Pipeline by ABIONYX Pharma SA, 2022
Dyslipidemia - Pipeline by Addpharma Inc, 2022
Dyslipidemia - Pipeline by Afimmune Biopharma Ltd, 2022
Dyslipidemia - Pipeline by Akcea Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Akeso Inc, 2022
Dyslipidemia - Pipeline by Amarin Corp Plc, 2022
Dyslipidemia - Pipeline by Arrakis Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by AstraZeneca Plc, 2022
Dyslipidemia - Pipeline by AVVA Pharmaceuticals AG, 2022
Dyslipidemia - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Dyslipidemia - Pipeline by Bio-Thera Solutions Ltd, 2022
Dyslipidemia - Pipeline by BioRestorative Therapies Inc, 2022
Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Cardax Inc, 2022
Dyslipidemia - Pipeline by Celltrion Inc, 2022
Dyslipidemia - Pipeline by Centaurus Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Centeer BioTherapeutics Ltd Co, 2022
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Dyslipidemia - Pipeline by CMG Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Corvidia Therapeutics Inc, 2022
Dyslipidemia - Pipeline by CVI Pharmaceuticals US Inc, 2022
Dyslipidemia - Pipeline by Daewon Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Daiichi Sankyo Co Ltd, 2022
Dyslipidemia - Pipeline by Delivra Corp, 2022
Dyslipidemia - Pipeline by Dicerna Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Dyslipidemia - Pipeline by Eccogene (Shanghai) Co Ltd, 2022
Dyslipidemia - Pipeline by Eli Lilly and Co, 2022
Dyslipidemia - Pipeline by Esperion Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Genu Pharma Co Ltd, 2022
Dyslipidemia - Pipeline by Gilead Sciences Inc, 2022
Dyslipidemia - Pipeline by Golden Biotechnology Corp, 2022
Dyslipidemia - Pipeline by Guangzhou Jiayue Pharmaceutical Technology Co Ltd, 2022
Dyslipidemia - Pipeline by Halo Therapeutics Ltd, 2022
Dyslipidemia - Pipeline by Handok Inc, 2022
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Dyslipidemia - Pipeline by HK inno.N Corp, 2022
Dyslipidemia - Pipeline by Huons Co Ltd, 2022
Dyslipidemia - Pipeline by Ildong Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Inovio Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Inversago Pharma Inc, 2022
Dyslipidemia - Pipeline by Japan Tobacco Inc, 2022
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Jenrin Discovery Inc, 2022
Dyslipidemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Dyslipidemia - Pipeline by JW Pharmaceutical Corp, 2022
Dyslipidemia - Pipeline by Korea United Pharm Inc, 2022
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Kowa Co Ltd, 2022
Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Kyttaro Ltd, 2022
Dyslipidemia - Pipeline by Kyung Dong Co Ltd, 2022
Dyslipidemia - Pipeline by Les Laboratoires Servier SAS, 2022
Dyslipidemia - Pipeline by Liid Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by LipimetiX Development Inc, 2022
Dyslipidemia - Pipeline by Lyndra Therapeutics Inc., 2022
Dyslipidemia - Pipeline by Madrigal Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, 2022
Dyslipidemia - Pipeline by MD Healthcare Inc, 2022
Dyslipidemia - Pipeline by Mochida Pharmaceutical Co Ltd, 2022
Dyslipidemia - Pipeline by Navipharm Co Ltd, 2022
Dyslipidemia - Pipeline by NewAmsterdam Pharma BV, 2022
Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, 2022
Dyslipidemia - Pipeline by Nissan Chemical Corp, 2022
Dyslipidemia - Pipeline by NorthSea Therapeutics BV, 2022
Dyslipidemia - Pipeline by NovalGen Ltd, 2022
Dyslipidemia - Pipeline by Novartis AG, 2022
Dyslipidemia - Pipeline by Nubiyota LLC, 2022
Dyslipidemia - Pipeline by NuSirt Biopharma Inc, 2022
Dyslipidemia - Pipeline by Omeros Corp, 2022
Dyslipidemia - Pipeline by Orient Pharma Co Ltd, 2022
Dyslipidemia - Pipeline by Pharmena SA, 2022
Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Rivus Pharmaceuticals Inc, 2022
Dyslipidemia - Pipeline by Saliogen Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Sequor Pharmaceuticals LLC, 2022
Dyslipidemia - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Dyslipidemia - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
Dyslipidemia - Pipeline by Sirnaomics Ltd, 2022
Dyslipidemia - Pipeline by SJT Molecular Research SL, 2022
Dyslipidemia - Pipeline by Staten Biotechnology BV, 2022
Dyslipidemia - Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Dyslipidemia - Pipeline by Sveikatal Inc, 2022
Dyslipidemia - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Dyslipidemia - Pipeline by Tetranov International Inc, 2022
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, 2022
Dyslipidemia - Pipeline by Viking Therapeutics Inc, 2022
Dyslipidemia - Pipeline by Yooyoung Pharm Co Ltd, 2022
Dyslipidemia - Pipeline by Yungjin Pharm Co Ltd, 2022
Dyslipidemia - Pipeline by Zydus Lifesciences Ltd, 2022
Dyslipidemia - Dormant Projects, 2022
Dyslipidemia - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dyslipidemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022